NASDAQ: ZURAZura Bio Ltd Stock
$3.62+0.31 (+9.37%)
Updated Apr 25, 2024
ZURA Price
$3.62
Fair Value Price
N/A
Market Cap
$157.81M
52 Week Low
$2.00
52 Week High
$14.00
P/E
-1.73x
P/B
2.66x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$60.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.36
Operating Cash Flow
-$15M
Beta
-0.43
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ZURA Overview
JATT Acquisition Corporation is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets the life sciences sector. JATT Acquisition was incorporated in 2021 and is based in Grand Cayman, Cayman Islands.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ZURA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ZURA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ZURA is good value based on its book value relative to its share price (2.66x), compared to the US Biotechnology industry average (5.8x)
P/B vs Industry Valuation
ZURA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ZURA due diligence checks available for Premium users.
Be the first to know about important ZURA news, forecast changes, insider trades & much more!
ZURA News
Valuation
ZURA fair value
Fair Value of ZURA stock based on Discounted Cash Flow (DCF)
Price
$3.62
Fair Value
-$0.02
Undervalued by
18,368.92%
ZURA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ZURA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.73x
Industry
15.41x
Market
40.97x
ZURA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.66x
Industry
5.8x
ZURA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ZURA's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.5M
Profit Margin
0%
ZURA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$100.8M
Liabilities
$21.3M
Debt to equity
0.36
ZURA's short-term assets ($100.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZURA's short-term assets ($100.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZURA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.1M
Investing
$0.0
Financing
$0.0
ZURA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ZURA vs Biotech Stocks
Zura Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.